Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.12 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)40.87K
Market Cap
$6.95M
Enterprise Value$8.61M
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$6.09M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,659,554
10 Day Avg. Volume57,038
30 Day Avg. Volume40,870
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue4.30
Enterprise Value/Gross Profit4.06
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CAB TechnologyBioAtla’s Conditionally Active Biologic (CAB) platform is a structural competitive advantage: by activating antibodies preferentially in tumors it can improve therapeutic selectivity and reduce systemic toxicity, which can raise clinical success odds and partner interest over time.
Internal Oncology PipelineMaintaining an internal pipeline provides multiple independent value drivers and 'shots on goal.' Sustained internal development capacity preserves upside from clinical progress, enables deal-making from a stronger negotiating position, and spreads program risk across assets.
Share Consolidation To Tighten Capital StructureThe 1-for-50 reverse split is a structural corporate action to consolidate the share base and tighten capital structure. This can help meet listing thresholds, reduce microcap trading volatility, and improve the company’s ability to transact with institutional counterparties over the medium term.
Bears Say
Persistent Cash BurnSustained heavy cash outflows mean BioAtla relies on external financing, asset sales, or partnerships to fund development. This structural cash profile constrains development timelines, increases dilution risk, and reduces negotiating leverage with partners or acquirers absent a durable cash-flow inflection.
Negative Stockholders' EquityErosion into negative equity and a materially shrunken asset base weakens balance-sheet resilience, limits borrowing capacity, and raises insolvency risk if financing sources tighten. This structural impairment reduces strategic optionality and may force value-destructive transactions.
Strategic Review And Program ReprioritizationA formal strategic review with program delays and workforce cuts signals constrained capital and potential reprioritization of clinical programs. Such structural changes can slow development, create execution risk, and indicate the company may need to monetize assets rather than progress internally.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.12 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $6.95M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.
How were Bioatla, Inc.’s earnings last quarter?
Currently, no data Available
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,659,554 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
27.13% Insiders
11.81% Mutual Funds
― Other Institutional Investors
58.07% Public Companies and
Individual Investors